AMINOSYN II 8.5%
Clinical safety rating: caution
Comprehensive clinical and safety monograph for AMINOSYN II 8.5% (AMINOSYN II 8.5%).
Aminosyn II 8.5% is a crystalline amino acid solution that provides essential and non-essential amino acids for protein synthesis when administered intravenously. It serves as a substrate for protein metabolism, promoting nitrogen retention and tissue repair.
| Metabolism | Amino acids are metabolized via normal pathways: transamination, deamination, and urea cycle. Branched-chain amino acids (leucine, isoleucine, valine) are primarily catabolized in skeletal muscle. |
| Excretion | Amino acids are primarily eliminated via metabolism; less than 10% is excreted renally as free amino acids. No significant biliary or fecal excretion. |
| Half-life | Variable; individual amino acids have half-lives ranging from minutes to hours. Clinical context: infusion rate and metabolic demand determine steady-state levels. |
| Protein binding | Variable; individual amino acids bind to plasma proteins to varying degrees; overall <30% bound. Primary binding proteins include albumin and globulins. |
| Volume of Distribution | Vd approximates total body water (0.45-0.75 L/kg) in healthy adults, reflecting distribution into extracellular and intracellular spaces. |
| Bioavailability | Oral: not applicable; intravenous: 100%. |
| Onset of Action | Intravenous: immediate upon infusion, as amino acids are rapidly available for protein synthesis and metabolic processes. |
| Duration of Action | Duration is dependent on infusion rate and metabolic utilization; effects persist as long as infusion is maintained, with rapid clearance after cessation. |
Intravenous infusion, typical adult dose is 1.0 to 1.5 g amino acids/kg/day, administered as part of total parenteral nutrition; rate not to exceed 0.1 g amino acids/kg/hour.
| Dosage form | INJECTABLE |
| Renal impairment | Not specifically adjusted by GFR; in renal impairment, use with caution, monitor fluid and electrolyte status; consider lower protein intakes in severe renal impairment (e.g., 0.6-0.8 g/kg/day) with appropriate supplementation. |
| Liver impairment | In hepatic encephalopathy, reduce dose or avoid; Child-Pugh score not directly used, but in severe hepatic impairment, restrict protein to 0.5-0.7 g/kg/day to prevent encephalopathy. |
| Pediatric use | Children: 2.0 to 3.0 g amino acids/kg/day intravenously; neonates and infants: 2.0 to 4.0 g/kg/day depending on age and clinical condition. |
| Geriatric use | No specific dose adjustment, but consider lower starting doses in elderly due to reduced organ function; monitor renal and hepatic function, and fluid balance. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for AMINOSYN II 8.5% (AMINOSYN II 8.5%).
| Breastfeeding | Amino acids are normal components of breast milk; supplemental doses likely safe. M/P ratio not established; monitor infant for any adverse effects. |
| Teratogenic Risk | No evidence of teratogenicity in animal studies. Fetal risks are primarily related to maternal malnutrition; amino acid supplementation may be beneficial. Inadequate studies in pregnant women; use only if clearly needed. |
| Fetal Monitoring |
■ FDA Black Box Warning
None.
| Serious Effects |
Hypersensitivity to any component; severe fluid overload; severe hepatic failure with hyperammonemia; inborn errors of amino acid metabolism (e.g., maple syrup urine disease, phenylketonuria).
| Precautions | Risk of hyperammonemia: Monitor ammonia levels in patients with hepatic impairment or inborn errors of metabolism. Correct electrolyte and fluid imbalances prior to administration. Use with caution in renal insufficiency (may require dose adjustment). |
| Food/Dietary | No specific food interactions. As parenteral nutrition, it bypasses the gastrointestinal tract. Monitor total caloric intake from other sources if any oral intake is allowed. |
Loading safety data…
| Monitor maternal electrolyte balance, acid-base status, blood urea nitrogen, and ammonia levels. Assess fetal growth and well-being if long-term use. |
| Fertility Effects | No known adverse effects on fertility. May support reproductive function in malnourished women. |
| Clinical Pearls |
| Aminosyn II 8.5% is a crystalline amino acid solution used as a component of parenteral nutrition. Verify central line patency before infusion. Monitor serum electrolytes, BUN, and ammonia levels. Do not use if solution is turbid or precipitate is present. Adjust infusion rate based on patient's metabolic needs and renal function. |
| Patient Advice | This medication provides essential proteins through your vein to support nutrition when you cannot eat by mouth. · Report any signs of infection at the IV site, such as redness, swelling, or pain. · Your blood will be monitored regularly to check kidney function and electrolyte levels. · Inform your healthcare provider if you have a history of liver or kidney disease. · Do not stop the infusion abruptly; it must be discontinued gradually under medical supervision. |